<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03949374</url>
  </required_header>
  <id_info>
    <org_study_id>4-2015-0730</org_study_id>
    <nct_id>NCT03949374</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate Efficacy and Safety of ROVASRO 10mg Versus CRESTOR 10mg in Hypercholesterolemic Patients</brief_title>
  <official_title>A 8-week, Single Center, Randomized, Open-label, Parallel-group, Non-inferiority Clinical Trial to Evaluate Efficacy and Safety of ROVASRO 10mg Versus CRESTOR 10mg in Hypercholesterolemic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 8 weeks, prospective, single center, randomized, open-label, parallel-group,
      non-inferiority study was performed from October 2015 to April 2018. This study as designed
      to evaluate the efficacy and safety of 10mg of the generic formulation (rosuvastatin,
      ROVASRO®) compared to the reference formulation (rosuvastatin, CRESTOR®) in patients with
      primary hypercholesterolemia and complex dyslipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2015</start_date>
  <completion_date type="Actual">June 1, 2018</completion_date>
  <primary_completion_date type="Actual">April 16, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>10mg of the generic formulation (rosuvastatin, ROVASRO®) versus 10mg of the reference formulation (rosuvastatin, CRESTOR®)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in the level of LDL-C</measure>
    <time_frame>8 weeks after treatment</time_frame>
    <description>Percentage change in the level of low-density lipoprotein-cholesterol (LDL-C)(mg/dL) from baseline to week 8 of drug treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Target achievement rate in the level of LDL-C</measure>
    <time_frame>8 weeks after treatment</time_frame>
    <description>Target achievement rate in the level of LDL-C from baseline to week 8 of drug treatment The LDL-C targets were defined as &lt;70 mg/dL for the very high risk group, &lt;100 mg/dL for the high risk group, &lt;130 mg/dL for the moderate risk group, and &lt;160 mg/dL for the low risk group (Committee. KCJ 2016).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in biochemical parameters : total cholesterol (mg/dL)</measure>
    <time_frame>8 weeks after treatment</time_frame>
    <description>Percentage changes in total cholesterol (mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biochemical parameters : triglyceride (mg/dL)</measure>
    <time_frame>8 weeks after treatment</time_frame>
    <description>Percentage changes in triglyceride (mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biochemical parameters : high-density lipoprotein-cholesterol(HDL-C)(mg/dL)</measure>
    <time_frame>8 weeks after treatment</time_frame>
    <description>Percentage changes in high-density lipoprotein-cholesterol(HDL-C)(mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biochemical parameters : apolipoprotein B(mg/dL)</measure>
    <time_frame>8 weeks after treatment</time_frame>
    <description>Percentage changes in apolipoprotein B(mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biochemical parameters : apolipoprotein A1(mg/dL)</measure>
    <time_frame>8 weeks after treatment</time_frame>
    <description>Percentage changes in apolipoprotein A1(mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biochemical parameters : high sensitivity C-reactive protein (hsCRP)(mg/L)</measure>
    <time_frame>8 weeks after treatment</time_frame>
    <description>Percentage changes in high sensitivity C-reactive protein (hsCRP)(mg/L).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>10mg of the generic formulation (rosuvastatin, ROVASRO®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taking 10mg of the generic formulation (rosuvastatin, ROVASRO®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10mg of the reference formulation (rosuvastatin, CRESTOR®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taking 10mg of the reference formulation (rosuvastatin, CRESTOR®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRESTOR, reference formulation of rosuvastatin</intervention_name>
    <description>Use of ROVASRO for hypercholesterolemia</description>
    <arm_group_label>10mg of the reference formulation (rosuvastatin, CRESTOR®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ROVASRO, generic formulation of rosuvastatin</intervention_name>
    <description>Use of CRESTOR for hypercholesterolemia</description>
    <arm_group_label>10mg of the generic formulation (rosuvastatin, ROVASRO®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Individuals aged between 19 and 80 years old.

          2. The following patients who belong to the low-risk group to the very-high risk group
             according to 2015 Korean guidelines for the management of dyslipidemia (Committee, KCJ
             2016).

               -  Very high risk group (coronary artery disease, ischemic stroke, peripheral
                  vascular disease) were not receiving lipid-lowering agents (statins) within 4
                  weeks of the screening, regardless of LDL-C levels

               -  High risk group (carotid artery disease, abnormal aneurysm, diabetes)* : LDL-C ≥
                  100 mg/dl

               -  Moderate risk group (2 or more major risk factors)* : LDL-C ≥ 130 mg/dl

               -  Low risk group (less than 1 major risk factors)* : LDL-C ≥ 160 mg/dl

                    -  If the patients taka a lipid-lowering agents (statin) within 4 weeks of
                       screening, enrolled them after wash-out for 4 weeks or more.

          3. Patients who voluntarily participated in the trial and obtained document consent.

        Exclusion Criteria:

          1. a history of acute arterial disease (patients with unstable angina myocardial
             infarction, transient ischemic attack, cerebrovascular disease, coronary artery bypass
             graft or percutaneous transluminal coronary angioplasty within 3 months prior to study
             enrollment)

          2. uncontrolled hypertension (systolic blood pressure ≥180mmHg or diastolic blood
             pressure ≥100mmHg)

          3. uncontrolled diabetes (hemoglobin A1c ≥9% or fasting glucose ≥160mg/dl)

          4. uncontrolled thyroid dysfunction (thyroid stimulation hormone ≥1.5 times the upper
             limits of normal (ULN))

          5. usage of antihyperlipidemic drugs (bile acid sequestrants, fibrates, niacin, etc.)
             within 4 weeks before enrollment

          6. a history of myopathy, rhabdomyolysis or elevated serum creatinine kinase (CK) more
             than 2 times the ULN

          7. chronic kidney disease (serum creatinine ≥2 times the ULN)

          8. elevated liver enzymes (aspartate aminotransferase (AST) or alanine aminotransferase
             (ALT) ≥2 times the ULN)

          9. a history of drug or alcohol abuse

         10. a history of gastrointestinal surgery or gastrointestinal tract disorders

         11. hypersensitivity to the components of this drug

         12. those who disagree with contraception

         13. pregnancy and/or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Cardiology, Cardiovascular Center, Severance Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 3, 2019</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

